Postprocedural pelvic infection

Postprocedural Pelvic Infection

⚠️

Key Point: Postprocedural pelvic infection encompasses infections of the uterus, adnexa, and surrounding pelvic structures arising after gynaecological or obstetric procedures. Prompt recognition and empirical antimicrobial therapy covering polymicrobial organisms — including anaerobes, enteric gram-negative bacilli, and sexually transmitted pathogens — is essential to prevent serious morbidity.

Introduction & Australian Epidemiology

Postprocedural pelvic infection is a recognised complication of a range of gynaecological and obstetric procedures, including caesarean section, hysterectomy, uterine evacuation (surgical management of miscarriage or termination of pregnancy), endometrial biopsy, hysteroscopy, intrauterine device (IUD) insertion, and in-vitro fertilisation (IVF) egg retrieval. The incidence varies by procedure: postcaesarean endometritis occurs in 1–3% of elective and up to 10–15% of emergency procedures; post-abortion infection occurs in approximately 1–5% of cases without prophylaxis.

In Australia, routine antibiotic prophylaxis has substantially reduced the incidence of postprocedural pelvic infection. However, infections still occur, particularly in women with bacterial vaginosis (BV), untreated STIs at the time of procedure, or in procedures performed under non-sterile conditions. The Australian Institute of Health and Welfare (AIHW) reports approximately 31% of births in Australia by caesarean section, making postcaesarean endometritis an important cause of postoperative morbidity.

Sexually transmitted infections — particularly Chlamydia trachomatis and Neisseria gonorrhoeae — can seed the upper genital tract during instrumentation if untreated at the time of the procedure. STI screening prior to elective uterine procedures reduces this risk significantly.

Microbiology & Pathophysiology

Postprocedural pelvic infection is typically polymicrobial, reflecting the ascent of vaginal and cervical flora into the upper genital tract during or after instrumentation. The microbial aetiology differs from community-acquired PID in the greater contribution of anaerobes and enteric organisms.

Anaerobes: Bacteroides fragilis, Prevotella spp., Peptostreptococcus spp. — dominant organisms in postcaesarean and post-hysterectomy infections. Produce beta-lactamases; metronidazole or beta-lactam/beta-lactamase inhibitor coverage is required.
Enteric gram-negative bacilli: Escherichia coli, Klebsiella pneumoniae — common in postcaesarean endometritis and pelvic cellulitis. Usually susceptible to first/second-generation cephalosporins and gentamicin.
Group B Streptococcus (GBS): Important cause of postpartum endometritis, particularly after labour. Usually susceptible to penicillin and cephalosporins.
Enterococcus faecalis: Present in a minority; not routinely covered by first-line cephalosporin regimens. Treat directed if isolated from cultures.
Chlamydia trachomatis / Neisseria gonorrhoeae: May cause infection after uterine instrumentation if present at the time of the procedure. Less common after obstetric procedures but important after elective gynaecological procedures. Add doxycycline if STIs were not excluded pre-procedure.
Mycoplasma hominis: Associated with postpartum fever and upper genital tract infection; resistant to beta-lactams. Doxycycline or clindamycin provides coverage.

Assessment of Postprocedural Pelvic Infection

Clinical Features

Postprocedural pelvic infection typically presents within 1–7 days of the procedure, although late presentations (up to 6 weeks) occur with STI-related infections or after IUD insertion. Key features include:

Fever: Temperature ≥38°C on two occasions ≥6 hours apart (or single temperature ≥38.5°C) after the first 24 hours post-procedure.
Lower abdominal/pelvic pain: Often worse than expected for the procedure performed. Uterine tenderness on palpation.
Abnormal uterine bleeding or discharge: Offensive lochia after obstetric procedures; purulent or malodorous discharge after gynaecological procedures.
Uterine subinvolution: Poorly involuting, tender uterus in the postpartum setting.
Wound infection signs: Erythema, induration, or discharge at abdominal incision or episiotomy site (assess separately from pelvic infection).
Systemic sepsis: Tachycardia, hypotension, rigors — require urgent assessment and IV antibiotics.

ℹ️

Differential Diagnosis: Urinary tract infection (UTI) is the most common cause of postoperative fever in the first 48 hours. Wound infection, haematoma, deep vein thrombosis (DVT), and drug fever must also be considered. Retained products of conception (RPOC) can cause or perpetuate endometritis post-abortion or postpartum.

Investigations

Essential

Blood Cultures (×2)

Collect prior to commencing antibiotics in all febrile patients with suspected pelvic infection. Bacteraemia is present in approximately 10–20% of severe cases. Required for antibiotic stewardship and directed therapy.
Essential

FBC, CRP, LFTs, UEC

Leucocytosis (WCC >11×10⁹/L) and elevated CRP support infection. Renal and hepatic function guides antibiotic dosing. Lactate if systemic sepsis suspected.
Essential

Urine MCS

UTI must be excluded as a cause of postoperative fever before attributing fever to pelvic infection. MSU or catheter specimen required.
Recommended

High Vaginal Swab / Endocervical NAAT

HVS for MCS and chlamydia/gonorrhoea NAAT. Positive results guide de-escalation or targeted therapy. Collection should not delay antibiotic initiation.
Recommended

Pelvic Ultrasound (USS)

Transvaginal or transabdominal USS to exclude tubo-ovarian abscess (TOA), pelvic haematoma, retained products of conception (RPOC), wound dehiscence, and vault haematoma post-hysterectomy. Essential if clinical response to antibiotics is suboptimal at 48–72 hours.
Selective

CT Abdomen/Pelvis

If USS inconclusive or peritonitis suspected. Identifies intra-abdominal collections, vault haematoma, pelvic abscess, and surgical complications (e.g. bowel injury, ureteric injury). Preferred modality in septic patients unresponsive to antibiotics.

Risk Stratification & Severity Assessment

NONSEVERE

Outpatient or Ward Management

Fever with uterine or pelvic tenderness; clinically well; tolerating oral medications; no systemic sepsis; no imaging evidence of abscess or collection.

Oral antibiotics; close monitoring; review in 48 hours

MODERATE

Inpatient IV Antibiotics

Unable to tolerate oral medications; persistent fever >38.5°C; significant pain; pelvic mass or haematoma on imaging; failed oral treatment within 48–72 hours; pregnancy.

IV antibiotics; surgical review for drainage if collection

SEVERE

Urgent Inpatient + Surgical Review

Systemic sepsis (tachycardia, hypotension, confusion); peritonitis; TOA; suspected anastomotic leak or bowel injury; bacteraemia; failed IV antibiotics at 72 hours.

Surgical or interventional radiology; ICU if septic shock

🚨

Sepsis Alert: Postprocedural pelvic infection can cause life-threatening sepsis, particularly due to Clostridium or Group A Streptococcus after uterine instrumentation. Rapidly progressive systemic illness after any uterine procedure requires urgent assessment, blood cultures, and IV broad-spectrum antibiotics without delay.

Empirical Therapy for Nonsevere Postprocedural Pelvic Infection

For mild-to-moderate postprocedural pelvic infection where the patient is clinically well and able to tolerate oral therapy, the following outpatient regimen provides polymicrobial coverage including anaerobes and enteric organisms.

💊

Amoxicillin-Clavulanate + Doxycycline

First-line oral regimen — covers anaerobes, enterics, chlamydia

Amoxicillin-Clavulanate 875/125 mg orally BD for 14 days

Doxycycline 100 mg orally BD for 14 days (add if STI not excluded pre-procedure)

Duration 14 days total

Review Clinical review at 48–72 hours mandatory

PBS Status ✓ PBS Listed

ℹ️

Postcaesarean / Postpartum: If breastfeeding, doxycycline should be used with caution (short-term use is generally considered acceptable by TGA; discuss risks and benefits). Amoxicillin-clavulanate is compatible with breastfeeding. Metronidazole 400 mg BD orally may be substituted for amoxicillin-clavulanate if penicillin allergy or preferred for anaerobic cover alongside a cephalosporin.

If Gonorrhoea Not Excluded Pre-Procedure

Add a single dose of ceftriaxone 500 mg IM/IV to cover N. gonorrhoeae at the time of initiating oral therapy.

Empirical Therapy for Severe Postprocedural Pelvic Infection

Inpatient IV therapy is required for severe or complicated postprocedural pelvic infection. Regimens must provide broad-spectrum polymicrobial coverage, including anaerobes, enteric gram-negative bacilli, streptococci, and chlamydia (if STI not excluded).

Initial IV Antibiotic Therapy

💊

Ceftriaxone + Metronidazole ± Doxycycline

First-line IV regimen — standard nonsevere penicillin allergy acceptable

Ceftriaxone 1–2 g IV once daily

Metronidazole 500 mg IV every 8–12 hours (or 400 mg oral BD if tolerating)

Doxycycline 100 mg IV/oral BD — add if STI not excluded prior to procedure

PBS Status ✓ PBS Listed

💊

Piperacillin-Tazobactam + Gentamicin

For sepsis or suspected bowel flora involvement — broadest-spectrum option

Pip-Tazo 4.5 g IV every 6–8 hours

Gentamicin 4–7 mg/kg IV once daily (extended-interval dosing; monitor levels)

Indication Systemic sepsis, suspected TOA with bowel flora involvement, or peritonitis after bowel surgery

PBS Status ✓ PBS Listed

Modification & Duration of Therapy

IV-to-oral step-down: After clinical improvement (afebrile ≥24 hours, tolerating oral intake, pain controlled), switch to oral amoxicillin-clavulanate 875/125 mg BD ± doxycycline 100 mg BD to complete a total of 14 days from treatment initiation.
Culture-directed de-escalation: Narrow antibiotic spectrum once blood culture and HVS results are available. Discontinue redundant agents based on sensitivity profile.
Non-response at 72 hours: If fever persists or clinical condition deteriorates, repeat imaging (CT pelvis) to identify undrained collection, RPOC, or surgical complication. Surgical or interventional radiology review required.
RPOC: Retained products of conception perpetuate endometritis and will not resolve with antibiotics alone. Suction curettage under antibiotic cover is required.

Penicillin Allergy — Alternative IV Regimens

💊

Clindamycin + Gentamicin

Alternative IV regimen for penicillin-allergic patients

Clindamycin 900 mg IV every 8 hours

Gentamicin 4–7 mg/kg IV once daily (extended-interval dosing)

Coverage Covers anaerobes (clindamycin), gram-negative rods (gentamicin), GBS, Mycoplasma hominis; add doxycycline if chlamydia not excluded

PBS Status ✓ PBS Listed

Considerations: Pelvic Infection with IUD in Situ

Pelvic infection after IUD insertion most commonly presents within 3 weeks of insertion. The risk is highest in the first 20 days; after this, the per-year risk returns to baseline. Most post-insertion infections are due to contamination of the upper genital tract during insertion by pre-existing cervical or vaginal flora — not the IUD itself.

Mild post-insertion PID: IUD can usually be retained if the patient responds to antibiotics within 72 hours. Current ASHM and WHO guidance supports IUD retention in mild PID that responds to treatment, as removal does not improve outcomes and exposes the patient to an unwanted pregnancy risk.
Severe post-insertion PID or TOA: Remove the IUD as part of management. Retained foreign body impairs antibiotic efficacy and source control.
Actinomycosis: A specific cause of post-IUD pelvic infection — see dedicated Pelvic Actinomycosis guideline for management. Requires prolonged high-dose penicillin.
Pre-insertion screening: STI screening (chlamydia and gonorrhoea NAAT) prior to IUD insertion in at-risk women reduces post-insertion pelvic infection. BV treatment before insertion is also recommended where detected.

Monitoring Parameters

48–72 Hours

Mandatory clinical review for all patients on outpatient or inpatient treatment. Assess fever resolution, pain response, uterine tenderness. If no improvement: escalate to IV therapy or review imaging. Check blood culture results.

Day 5–7

Review culture and NAAT results. Directed de-escalation if organism identified. Ensure RPOC excluded by USS if endometritis persists. Assess wound healing if abdominal incision involved.

End of Treatment (Day 14)

Clinical review: confirm symptom resolution, no fever, return to normal uterine consistency. CRP and WCC if elevated at baseline. Repeat imaging if previous abscess or collection documented.

6 Weeks

Post-procedure review (standard of care). Assess for chronic pelvic pain, adhesion formation symptoms, or concern for tubal pathology. Fertility counselling if relevant. STI test of cure if applicable.

Special Populations

🤰 Postpartum / Breastfeeding

Postpartum endometritis after vaginal delivery or caesarean section is the most common form of postprocedural pelvic infection in Australia. Breastfeeding compatibility of antibiotics must be considered.

Safe in breastfeeding: Amoxicillin-clavulanate, cephalosporins, clindamycin, metronidazole (short-term), and gentamicin are all compatible with breastfeeding at standard doses.
Doxycycline: Generally avoided in prolonged breastfeeding (theoretical dental staining risk); short courses (≤3 weeks) are considered acceptable by most guidelines. Discuss with the patient.
Postcaesarean: First-line prophylaxis (cefazolin 2 g IV) reduces endometritis risk by 60–70%. If infection occurs despite prophylaxis, use a different antibiotic class for treatment.

🛡️ Immunocompromised

Immunocompromised patients (transplant recipients, those on long-term corticosteroids, patients with haematological malignancy) are at increased risk of severe postprocedural infection and unusual organisms.

Lower threshold for IV therapy: Initiate IV broad-spectrum antibiotics earlier; lower threshold for imaging and surgical review.
Fungal coverage: Consider empirical antifungal therapy if prolonged hospitalisation, prior antibiotics, or systemic candidiasis risk factors are present.
Drug interactions: Review antibiotic interactions with immunosuppressants (e.g. metronidazole with calcineurin inhibitors; azoles with tacrolimus).

🫘 Renal Impairment

Gentamicin is renally cleared and requires dose adjustment. Piperacillin-tazobactam dose should also be reduced in severe renal impairment.

Gentamicin extended-interval dosing: In CrCl <60 mL/min, extend interval or reduce dose — use Hartford nomogram or pharmacy guidance. Monitor trough levels.
Pip-Tazo: Reduce dose to 2.25 g every 6–8 hours in CrCl <20 mL/min.
Ceftriaxone and metronidazole: No dose adjustment required for mild-moderate renal impairment. Metronidazole: use with caution in severe renal impairment.

👵 Older Women / Post-Menopause

Post-menopausal women undergoing uterine procedures (e.g. hysteroscopy, endometrial biopsy, IUCD insertion for HRT) are at risk of postprocedural infection, though STIs are less commonly implicated.

Aetiology: Predominantly enteric gram-negative bacilli and anaerobes; STI cover is usually not required unless clinically indicated.
Prophylaxis: For hysteroscopy in post-menopausal women, antibiotic prophylaxis is recommended in high-risk settings (e.g. immunocompromise, prior pelvic surgery, cardiac valvular disease).
Vaginal atrophy: May mask typical clinical signs of infection; lower threshold for investigation and treatment if febrile after uterine procedure.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander women have higher rates of caesarean section complications, higher background STI prevalence, and greater difficulty accessing antenatal and peri-procedural care, particularly in remote and very remote communities. These factors increase the risk of both postprocedural infection and delayed diagnosis.

High Background STI Prevalence

In communities with elevated chlamydia and gonorrhoea prevalence, ensure STI screening before elective uterine procedures. Empirical ceftriaxone coverage should be included in postprocedural infection regimens in these settings even if STI NAAT results are pending.

Access to Care

Post-discharge follow-up after caesarean section or gynaecological procedures may be challenging in remote communities. Ensure robust discharge planning with clear return-to-care instructions, written in plain language, and preferably discussed with an Aboriginal Health Worker or liaison officer.

Culturally Safe Care

Engage female Aboriginal Health Workers or female nursing staff for intimate examinations where possible. Reproductive health discussions should respect cultural values around fertility, family planning, and Country. Telehealth may be used for follow-up in remote settings.

Oral Adherence Challenges

Fourteen-day oral antibiotic courses are associated with suboptimal adherence in remote settings. Consider directly observed therapy (DOT), depot preparations where applicable, or hospital-in-the-home models for IV antibiotic completion to ensure treatment completion.

Antibiotic Stewardship (ACSQHC NSQHS Standard 3)

ℹ️

Prophylaxis is the cornerstone of prevention: Single-dose cefazolin (2 g IV) prior to skin incision for caesarean section reduces postoperative endometritis by 60–70%. Similarly, doxycycline 100 mg orally before surgical uterine evacuation and azithromycin 500 mg IV at caesarean significantly reduces infection rates. Prophylaxis should be given <60 minutes before incision.

Culture before treating: Blood cultures and endocervical/HVS specimens should be collected before antibiotic commencement to allow directed therapy and de-escalation once results are available.
De-escalation is mandatory: Broaden-spectrum agents (pip-tazo, gentamicin) should be stepped down once the causative organism and susceptibility are known. Avoid prolonged pip-tazo use without clear indication — associated with C. difficile and enterococcal superinfection.
14-day courses are standard: Do not truncate treatment to <14 days for confirmed pelvic infection — shorter courses are associated with treatment failure and relapse.
Avoid fluoroquinolones: High rates of resistance among E. coli and gonorrhoea in Australia render fluoroquinolones unreliable as empirical agents for pelvic infection.

Follow-Up & Prevention

Preventing Postprocedural Pelvic Infection

1

Pre-procedure STI Screening

Screen for chlamydia and gonorrhoea before elective uterine procedures in sexually active women under 30 or with STI risk factors. Treat before proceeding if positive.

2

Antibiotic Prophylaxis

Administer evidence-based prophylaxis: cefazolin 2 g IV for caesarean section; doxycycline 100 mg oral for surgical uterine evacuation. Give within 60 minutes of skin incision.

3

Treat BV Before Procedure

Bacterial vaginosis identified before elective instrumentation should be treated prior to the procedure to reduce post-procedural infection risk.

4

Aseptic Technique

Strict aseptic technique during all uterine instrumentation, including appropriate skin and vaginal preparation, sterile instruments, and minimising procedure duration.

References

01
Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
02
Australian Institute of Health and Welfare (AIHW). Australia's Mothers and Babies 2021. Canberra: AIHW; 2023. Available at: https://www.aihw.gov.au
03
Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after caesarean section. Cochrane Database Syst Rev. 2014;(10):CD007482.
04
Australasian Sexual Health Alliance (ASHA). Australian STI Management Guidelines — Pelvic Inflammatory Disease. 2023. Available at: https://sti.guidelines.org.au
05
Harper LM, Kilgore M, Szychowski JM, et al. Adjunctive azithromycin prophylaxis for cesarean delivery. N Engl J Med. 2016;375(13):1231–1241.
06
National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE Guideline NG126. London: NICE; 2019.
07
Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Antibiotic prophylaxis in obstetric and gynaecological procedures. RANZCOG College Statement C-Obs 23. Melbourne: RANZCOG; 2022.
08
Farquhar C, Vandekerckhove P, Watson A, Vail A, Wiseman D. Barrier agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev. 2000;(2):CD000475.
09
Australian Commission on Safety and Quality in Health Care. NSQHS Standards — Antimicrobial Stewardship Standard. Sydney: ACSQHC; 2021.
10
French LM, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database Syst Rev. 2004;(4):CD001067.
11
Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2023. Sydney: Kirby Institute, UNSW Sydney; 2023.
12
Ross J, Guaschino S, Cusini M, Jensen J. 2017 European IUSTI guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018;29(2):108–114.